Beam Therapeutics Ret. on equity
What is the Ret. on equity of Beam Therapeutics?
The Ret. on equity of Beam Therapeutics Inc. is -16.22%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Beam Therapeutics
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Companies with ret. on equity similar to Beam Therapeutics
- Cadogan Petroleum plc has Ret. on equity of -16.25%
- Bal Pharma has Ret. on equity of -16.24%
- Xinjiang Tianye Water Saving Irrigation System has Ret. on equity of -16.24%
- Serengeti Resources has Ret. on equity of -16.24%
- Terramin Australia has Ret. on equity of -16.23%
- Arrow Greentech has Ret. on equity of -16.22%
- Beam Therapeutics has Ret. on equity of -16.22%
- Rockport Capital Corp has Ret. on equity of -16.21%
- Clarke has Ret. on equity of -16.20%
- Evotec SE has Ret. on equity of -16.20%
- Seneca Growth Capital VCT has Ret. on equity of -16.20%
- Trident Acquisitions has Ret. on equity of -16.18%
- Lottery.com Inc has Ret. on equity of -16.18%